VivoSeq
Neurology

Primary Progressive Multiple Sclerosis

18

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Primary Progressive Multiple Sclerosis is an emerging landscape with 18 programs across 12 companies. The most active players are Santhera Pharmaceuticals, Teva, Boehringer Ingelheim. 2 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Santhera Pharmaceuticals

1 program

Phase 1Teva logo

Teva

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

16 of 18 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody211%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

18

clinical trials

Completed12 · 67%
Active, not recruiting2 · 11%
Not yet recruiting1 · 6%
No longer available1 · 6%
Recruiting1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
Recruiting·RRennes University Hospital·Phase 1·NCT06592703·10 enrolled
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Active, not recruiting·Roche logoRoche·Phase 3·NCT04548999·769 enrolled
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Active, not recruiting·Roche logoRoche·Phase 3·NCT04035005·1,013 enrolled
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
Not yet recruiting·SStanford University·Phase 1·NCT06900192·10 enrolled
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Completed·Roche logoRoche·Phase 3·NCT01194570·735 enrolled
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
Completed·Roche logoRoche·Phase 2/3·NCT00087529·439 enrolled
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Completed·UUniversity of Calgary·Phase 2·NCT02913157·35 enrolled
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Completed·Sanofi logoSanofi·Phase 3·NCT04458051·767 enrolled
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Completed·Roche logoRoche·Phase 3·NCT02688985·131 enrolled
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Completed·—·Phase 2·NCT02959658·54 enrolled
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Completed·Teva logoTeva·Phase 2·NCT02284568·374 enrolled
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
Completed·JJoanne Kurtzberg, MD·Phase 1·NCT04943289·20 enrolled
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
Completed·Roche logoRoche·N/A·NCT03593590·1,710 enrolled
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
Completed·Roche logoRoche·Phase 3·NCT03606460·141 enrolled
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00950248·85 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)